TREATMENT OF CANCER WITH DUAL TARGETING OF CD47 AND EGFR
Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Europäisches Patentamt - (2017) vom: 15. Juni Zur Gesamtaufnahme - year:2017 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WEISSMAN IRVING L [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2017-06-15, Last update posted on www.tib.eu: 2024-04-01, Last updated: 2024-04-09 |
|---|
| Patentnummer: |
CA3005911 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003243893 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003243893 | ||
| 003 | DE-627 | ||
| 005 | 20240409143703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2017 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003243893 | ||
| 035 | |a (EPA)CA3005911 | ||
| 035 | |a (EPA)59013321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WEISSMAN IRVING L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TREATMENT OF CANCER WITH DUAL TARGETING OF CD47 AND EGFR |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2017-06-15, Last update posted on www.tib.eu: 2024-04-01, Last updated: 2024-04-09 | ||
| 520 | |a Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MCKENNA KELLY MARIE |e verfasserin |4 aut | |
| 700 | 0 | |a WILLINGHAM STEPHEN |e verfasserin |4 aut | |
| 700 | 0 | |a HO DORIS PO YI |e verfasserin |4 aut | |
| 700 | 0 | |a DALERBA PIERO D |e verfasserin |4 aut | |
| 700 | 0 | |a VOLKMER JENS-PETER |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2017) vom: 15. Juni |
| 773 | 1 | 8 | |g year:2017 |g day:15 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/59013321/publication/CA3005911A1?q=CA3005911 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2017 |b 15 |c 06 | ||